Reviva Pharmaceuticals I... (RVPH)
NASDAQ: RVPH
· Real-Time Price · USD
0.35
-0.41 (-54.17%)
At close: Jun 26, 2025, 3:59 PM
Reviva Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 352.01K | 877.93K | 1.14M |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -352.01K | -877.93K | -1.14M |
Operating Income | -30.8M | -34.5M | -36.75M | -40.69M | -39.5M | -37.29M | -30.14M | -23.59M | -24.31M | -20.5M | -19.41M | -15.68M | -10.1M | -6.67M | -4.7M | -3.69M |
Interest Income | 361.37K | 471.07K | 509.58K | 525.05K | 498.96K | 467.69K | 425.44K | 330.05K | 183.03K | 57.19K | 7.68K | n/a | 148.00 | 80.33K | 90.22K | 115.22K |
Pretax Income | -29.9M | -33.37M | -35.49M | -40.07M | -39.24M | -37.62M | -30.66M | -23.56M | -24.32M | -19.89M | -18.66M | -14.93M | -8.52M | -6.35M | -4.74M | -3.98M |
Net Income | -29.92M | -33.38M | -35.51M | -40.09M | -39.26M | -37.65M | -30.68M | -23.58M | -24.34M | -19.91M | -18.67M | -14.94M | -8.52M | -6.36M | -4.74M | -3.98M |
Selling & General & Admin | 7.89M | 7.8M | 8.19M | 8.72M | 8.08M | 8.05M | 7.31M | 5.24M | 5.36M | 5.18M | 4.98M | 5.39M | 5.25M | 4.48M | 3.93M | 3.26M |
Research & Development | 22.91M | 26.7M | 28.56M | 31.97M | 31.42M | 29.24M | 22.83M | 18.35M | 18.95M | 15.31M | 14.43M | 10.29M | 4.85M | 2.48M | 1.06M | 723.74K |
Other Expenses | n/a | n/a | 5.19K | 5.17K | -9.32K | -9.32K | -14.51K | -14.49K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 30.8M | 34.5M | 36.75M | 40.69M | 39.5M | 37.29M | 30.14M | 23.59M | 24.31M | 20.5M | 19.41M | 15.68M | 10.1M | 6.67M | 4.7M | 3.69M |
Interest Expense | 18.5K | -6.63K | -5.87K | 1.73K | 5.9K | 159.61K | 203.22K | 198.14K | 190.72K | 57.42K | 8.46K | 4.33K | 4.1K | 1.08M | 1.23M | 1.32M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 30.8M | 34.5M | 36.75M | 40.69M | 39.5M | 37.29M | 30.14M | 23.59M | 24.31M | 20.5M | 19.41M | 15.68M | 10.1M | 6.67M | 4.7M | 3.69M |
Income Tax Expense | 19.51K | 10.2K | 22.32K | 21.37K | 16.95K | 29.89K | 19.64K | 20.13K | 20.78K | -261.86K | -261.62K | -264.64K | -267.47K | 6.26K | 4.7K | 25.8K |
Shares Outstanding (Basic) | 33.15M | 33.8M | 30.56M | 29.89M | 27.56M | 24.03M | 22.43M | 21.83M | 20.45M | 19.27M | 18.47M | 18.47M | 14.43M | 18.46M | 12.87M | 9.23M |
Shares Outstanding (Diluted) | 33.15M | 33.8M | 30.56M | 29.89M | 27.56M | 24.03M | 22.43M | 21.83M | 20.45M | 19.27M | 18.47M | 18.47M | 14.43M | 18.46M | 12.87M | 9.23M |
EPS (Basic) | -0.9 | -1.11 | -1.3 | -1.59 | -1.65 | -1.69 | -1.44 | -1.17 | -1.27 | -1.13 | -1.07 | -0.9 | -0.61 | -0.52 | -0.64 | -0.82 |
EPS (Diluted) | -0.9 | -1.11 | -1.3 | -1.59 | -1.65 | -1.69 | -1.44 | -1.17 | -1.27 | -1.13 | -1.07 | -0.9 | -0.61 | -0.52 | -0.64 | -0.82 |
EBITDA | -21.52M | -24.66M | -35.27M | -39.39M | -38.57M | -36.49M | -29.45M | -23.18M | -24.11M | -20.76M | -19.68M | -15.77M | -10.1M | -6.59M | -4.62M | -3.58M |
EBIT | -29.88M | -33.64M | -35.99M | -40.21M | -39.52M | -37.29M | -30.14M | -23.59M | -24.31M | -16.53M | -12.97M | -7.45M | -1.87M | -1.87M | -2.38M | -2.38M |
Depreciation & Amortization | 781.64K | 1.38M | 1.48M | 1.3M | 933.89K | 794.27K | 724.4K | 443.32K | 221.79K | 34.32K | 61.24K | 295.07K | 384.23K | 110.06K | 56.22K | 578.00 |